Skip to main content

Table 1 Basic characteristics of study groups

From: The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus

Characteristic

Co

CoCin

DiabCo

DiabCin

Pdiabetes

Ptreatment

Pinteraction

Blood glucose (mmol/l)

5.8 ± 0.1

6.2 ± 0.1

30.8 ± 0.5*

29.3 ± 1.4*

<0.001

0.460

0.209

Water intake (ml/gBW/day)

0.078 ± 0.002

0.090 ± 0.002

0.787 ± 0.006*

0.597 ± 0.013*

<0.001

<0.001

<0.001

Heart weight (g)

1.20 ± 0.06

1.24 ± 0.07

0.91 ± 0.04*

0.84 ± 0.03*

<0.001

0.805

0.278

Body weight (g)

480.7 ± 17.6

477.8 ± 20.9

293.5 ± 11.1*

247.6 ± 14.8*

<0.001

0.150

0.202

Heart weight/body weight

0.249 ± 0.008

0.259 ± 0.008

0.311 ± 0.009*

0.348 ± 0.015*

<0.001

0.026

0.196

  1. The values of blood glucose, daily water intake, heart weight, body weight (BW) and heart weight to body weight ratio are shown of the study groups—vehicle-treated controls (Co), cinaciguat-treated controls (CoCin), vehicle-treated diabetic (DiabCo) and cinaciguat-treated diabetic (DiabCin) groups. Values are mean ± SEM of 10–12 experiments per group
  2. * P < 0.05 vs. Co
  3. P < 0.05 vs. DiabCo (Tukey HSD test)